All Episodes
My Pharma Reviews — 52 episodes
The GLP-1 Reckoning
US Tariffs on Generic Medicines
India's GLP-1 Shakeout Is Coming
The $300 Billion Super-Cliff
Dr. Reddy's Semaglutide Stall In The GLP-1 Race
The Culture Gap
Episode 10: Biology Is The Software
Episode 9: The Last Prescription
Episode 8: The Gatekeeper Who Is Leaving the Building
Episode 7: The Capital Allocation Crisis
Episode 6: The Talent That Got Away
Episode 5: The Day the Patent Fell
Episode 4: The Qualification Gap
Episode3: The Biologics Report Card
Episode 2: The Generics Trap
Episode 1: The Bio-Health Supercycle
One Country. Three Markets
India's CDMO Moment
Organisational Theatre
Follow the Money
The Fallacy of Size
The Great Indian Pharma Split
Sun Pharma's Billion-Dollar Bet
One Shot. Done.
The Wrong Scoreboard
AI Run Rates vs. Pharma Blockbusters
You Make the Drug. They Own the Patient
APIs, CDMOs, Biologics, and AI
Hard to Copy Is Easy to Value
The Indian-CEO Alpha
India’s Semaglutide Market Is A Red Ocean
Biocon At The Crossroads.
The Imagination Deficit
The Five Truths Reshaping Indian Pharma
The $45 Billion Lesson Indian Pharma Isn't Learning
Cheap Semaglutide, Costly Reputations
India-Specific Disease R&D
Sun Pharma’s Organon Deal
The Optimizer CEO's Trap
Character: The Last Human Edge in an AI World
The Comfort Trap of Indian Pharma
Europe’s Pharma Paradox
Regulation is the Moat, Not the Enemy
India's Pharma Miracle
From Field Force to Force Multipliers
The Risk Pharma Refuses to Model
Vas Narasimhan-Anthropic Appointment
Healthcare’s Power Shift
10,000 Hours - What It Means for Pharma
The Next Pharma Gold Rush
Who Will Reinvent Indian Pharma?
China Just Connected Every Wearable Device to Its Health System